ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGY Allergy Therapeutics Plc

7.40
0.20 (2.78%)
07 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 2.78% 7.40 6.70 7.50 7.24 6.90 7.10 444,115 16:35:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 55.2M -40.22M -0.0084 -8.45 343.18M
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 7.20p. Over the last year, Allergy Therapeutics shares have traded in a share price range of 1.88p to 7.25p.

Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £343.18 million. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -8.45.

Allergy Therapeutics Share Discussion Threads

Showing 4576 to 4596 of 5375 messages
Chat Pages: Latest  191  190  189  188  187  186  185  184  183  182  181  180  Older
DateSubjectAuthorDiscuss
07/2/2023
13:23
What are we waiting for here? The share is currently suspended. Thanks.
farmergeorge
06/2/2023
18:26
coinbase, it wont be. We will get answers imminently for certain. There are lots of questions


The peanut and Birch/Grass projects are now so vital to me, that I have taken to lighting candles and bought a prayer mat!! I have also bought a tin helmet!

I suggest others do the same.

jimmyloser
06/2/2023
17:32
The silence is deafening.
coinbase
05/2/2023
15:04
I jumped for a large loss and took back what i could. I never hold suspended shares. Got AGY wrong and there were signs.
raleigh43
03/2/2023
20:38
Yep a stitch up bordering on fraud.
jpuff
03/2/2023
17:25
The big risk we run is that the company goes private as part of the refinancing, where we are offered a choice of a low price for our shares or to stay locked in to a private entity with little to no say in its running. Even this latter option may only be a possibility if over 10% fail to accept (they fail to get to 90% acceptances). In my more paranoid moments I think the changed provision in the new Articles for selling untraced shareholders' shares is to facilitate a squeeze-out over time.
If they had set out to create favourable preconditions for a take-private they could not have done a better job. Shares suspended, price at an all-time low, company seeking finance with its back to the wall, shareholders powerless. I'm not saying this was planned, but if Llobet and others on the board end up in the new private entity it would not look good.

1kckeith
02/2/2023
16:20
????????????????????????
jimmyloser
30/1/2023
19:34
Probably another sh1t sandwich
jpuff
30/1/2023
16:20
Following on from YorkieMike, one could be forgiven for believing that we may not see anything until after the AGM?

ANY VIEWS AS TO WHAT IS COOKING HERE?

jimmyloser
20/1/2023
11:07
>>>jl

I believe that the SE rules state that the annual report has to be available to shareholders 21 days before the AGM, so I would assume they will need to issue the annual report today or on Monday, unless they are prepared to postpone the AGM (again) which is currently scheduled for Tuesday February 7th. I suspect the shares will resume trading as soon as the report is issued, on that basis I would assume the report will most likely be issued on Monday, with trading resumed either later on Monday or on Tuesday

timbo003
20/1/2023
10:02
Thank you. A bargain, if someone bites.

I note that we have no mention of a return to market in this mornings RNS.

jimmyloser
20/1/2023
09:43
JIMMY
30p! 10p cash and the rest 20p in shares

wizzkid211
20/1/2023
08:58
wizzkid
Thanks, please elaborate for us all. What do you believe is circa a 'reasonable price'?
jl

jimmyloser
20/1/2023
08:53
Someone is bound to take over at a reasonable price
wizzkid211
20/1/2023
08:44
Feels a a relief that I'll be left with my whopping loses here rather than losing the lot!
jpuff
20/1/2023
07:08
The Group expects revenue for the six months ended 31 December 2022 to be GBP39.9m (2021: GBP48.7m) representing a reduction of 18% compared to last year. This decrease in revenue is primarily due to the previously announced voluntary short-term pause in production in the UK, together with the previous strategic streamlining of some older products in the portfolio. In the second half of the financial year, the Group expects sales to continue at a similar level compared to last year, before recovering in the next financial year.

The cash balance at 31 December 2022 was GBP15.2m (30 June 2022: GBP20.5m). Pursuant to the subscription and debt financing announced on 29 September 2022, the Company has received GBP7m from the issue of new ordinary shares and expects to receive GBP10m from the issue of loan notes on 28 February 2023.

As previously announced, the Company is reviewing funding options following the temporary pause in production that has resulted in the need for additional near-term funding. The Company is increasingly confident that its funding discussions will result in a positive outcome and will update the market in due course.

The Company is actively working to finalise the audit and publication of its annual report and accounts for the year ended 30 June 2022 and will update the market in due course.

wizzkid211
14/1/2023
19:29
Thank you for your erudite post. I take comfort from the fact that we have technology that allows us to ask any question and hopefully have them answered publiclyFor my sins I trust Manuel.
jimmyloser
14/1/2023
18:42
Call me paranoid but this company has lost my trust and I fear the next step will be some form of cram-down refinancing that destroys our economic interest - e.g. a taking private on rubbish terms where the insiders participate in newco.

1. The notice of the AGM was hard to find and the Stock Exchange announcement was devoid of detail
2. the time and place are inconvenient to outsiders
3. they are proposing to reappoint the entire board despite their catastrophic mismanagement
4. they will issue new Articles. I am super-suspicious but must admit could see nothing new that was dangerous to us minority shareholders. Look at Appendix 1 of this:hxxps://www.allergytherapeutics.com/media/1432/01_nom_allergy_ar22_cl.pdf
any views?
5. The announcement of the company's difficulties actually happened on 8/12 hidden in another announcement. In the preceding 2 weeks the shares dropped from an already-low 15p to 13p (13%) before falling to 11p on this announcement.

How did we get here? I have been through the history and here is my theory / speculation. The key factors appear to have been:
a) the voluntary suspension of production in October (peak production period pre-season)
b) the consequent loss of the NatWest loan facility
c) the inadequacy of the 'insider funding' completed in September (just before a)):

So the situation seems to me to be (working backwards):
• The shares are currently suspended because the accounts had not been approved by 31 December 2022. I assume there is a going concern issue owing to the missing NatWest funding
• On 8 December the company issued an obscure warning of its financial difficulties.
• AGY's trading is projected to be negatively affected by the ‘pause’ in production announced early in October, which triggered NatWest’s refusal to lend. As the pause in manufacturing was voluntary, the impact on the NatWest facility should have been anticipated and managed. Furthermore, the market should have been informed of something of this scale promptly when management had made its plans.
• The £17m insider funding (of which the £10m gross loan amount remains to be lent) was presumably done in the knowledge of the production pause, announced days later, and hence its anticipated impact. It is to be assumed that this £17m gross was expected to suffice to meet the financial hole left by the production pause. However, apparently this is not the case – or the accounts delay and consequent suspension is owing to the £10m not being expected to be forthcoming, on the agreed terms, in February. I might be paranoid, but the Investors are no fools so possibly the funding was staggered in this way in order to give them an opportunity to renegotiate the terms.

If my fears are founded, then we have little power with 82% of the company in insider hands - unless someone knows Abbott, who might be a dissenter (hence the board member leaving). If enough of us to represent 10% of the total are united, we can refuse the compulsory purchase of our shares (a 'squeeze out' that can only take place if they achieve 90% acceptances) in the take-private scenario I fear.

1kckeith
14/1/2023
14:04
>>>>jl

I intend to go along (despite the treck) and hold them to account, although I see that they intend to provide a video link for the meeting

timbo003
14/1/2023
13:34
timbo003,
Thanks. I just feel that there is more to this than is meeting the eye. Clearly the £10million revolving credit from NatWest is at the centre of this suspension along with the shutdown (expected or unexpected). We have a sold business here with heavyweight investors, 600 people employed and good prospects but they are prone to setbacks.
Hopefully they can sort this setback out and deliver all that is promised.

Worthing, is another planet for me - lol

jimmyloser
13/1/2023
16:24
any thoughts on what next and when?
jimmyloser
Chat Pages: Latest  191  190  189  188  187  186  185  184  183  182  181  180  Older

Your Recent History

Delayed Upgrade Clock